During the past decade, FDI Clinical Research conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 9 clinical trials were completed, i.e. on average, 36% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 6 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

Out of the total clinical trials conducted in "FDI Clinical Research" #1 sponsor was "Bristol-Myers Squibb" with 3 trials, followed by "Gilead Sciences" with 3 trials sponsored, "Janssen Research & Development, LLC" with 3 trials sponsored, "Harvard School of Public Health (HSPH)" with 2 trials sponsored and "Axcella Health, Inc" with 2 trials sponsored. Other sponsors include 13 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "FDI Clinical Research" #1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "FDI Clinical Research" with 1 trials as a collaborator, "FDI Clinical Research of Puerto Rico" with 1 trials as a collaborator, "Janssen Biotech, Inc." with 1 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "FDI Clinical Research" are "Non Alcoholic Steatohepatitis (NASH)" (3 trials), "Dyslipidemias" (2 trials), "Hypertension" (2 trials), "Liver Fibrosis Due to NASH" (2 trials) and "Nonalcoholic Fatty Liver Disease" (2 trials). Many other conditions were trialed in "FDI Clinical Research" in a lesser frequency.

Most popular intervention types in "FDI Clinical Research" are "Drug" (21 trials), "Biological" (7 trials), "Other" (4 trials), "Behavioral" (1 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "Nivolumab" (3 trials), "Daratumumab" (2 trials), "Docetaxel" (2 trials) and "SIM" (2 trials). Other intervention names were less common.

The vast majority of trials in "FDI Clinical Research" are 29 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "FDI Clinical Research". undefined are not yet recruiting, 11 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in FDI Clinical Research, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in FDI Clinical Research, 3 "Phase 1" clinical trials were conducted, 18 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".